4连板塞力医疗：旗下联营企业治疗性降压疫苗项目试验能否成功还存在重大不确定性

Core Viewpoint - The recent market interest in innovative drug business has led to significant attention on the therapeutic hypertension vaccine project by the company's affiliate, Huajiyuan Biotech, which still faces major uncertainties regarding trial success [1] Group 1: Company Overview - The company holds a 15.61% stake in Huajiyuan Biotech, which was invested in January 2020 for an amount of 10.666 million yuan [1] - Huajiyuan Biotech reported an expected revenue of 26,800 yuan for 2024, with a net loss of 2.3823 million yuan [1] Group 2: Project Status - The therapeutic hypertension vaccine project HJY-ATRQβ-001 has completed the proof of concept (POC) and preclinical studies [1] - The project received acceptance for a new drug clinical trial application (IND) from the National Medical Products Administration (NMPA) on June 6, 2025, but still requires successful completion of Phase I and Phase II clinical trials [1] - There remains significant uncertainty regarding the success of these trials [1]